Skip to main content

Merck & Co., Inc.

corporate_fare Company Profile

Merck & Co., Inc.

MRK·NYSE·Life Sciences·CIK 0000310158

Merck & Co., Inc. is a global healthcare company providing innovative health solutions through prescription medicines, including biologic therapies, vaccines, and animal health products. The company manages its operations primarily on a product basis, with two reportable operating segments: Pharmaceutical and Animal Health. The Pharmaceutical segment encompasses human health pharmaceutical and vaccine products. Human health pharmaceutical products are therapeutic and preventive agents, generally sold by prescription, for treating human disorders. Merck sells these products mainly to drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers like health maintenance organizations and pharmacy benefit managers. Human health vaccine products include preventive pediatric, adolescent, and adult vaccines, sold primarily to physicians, wholesalers, distributors, and government entities. The Animal Health segment focuses on discovering, developing, manufacturing, and marketing a broad range of veterinary pharmaceutical and vaccine products, alongside health management solutions and services. These offerings aim to prevent, treat, and control diseases in all major livestock and companion animal species. This segment also provides a comprehensive suite of digitally connected identification, traceability, and monitoring products. Merck sells its animal health products to veterinarians, distributors, animal producers, farmers, and pet owners.

Merck & Co., Inc. (NYSE:MRK) is a publicly traded company in the Life Sciences sector. Wiseek monitors MRK SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
  • Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
  • Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
  • Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
  • Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$65.01B
Net Income
$18.25B
Diluted EPS
$7.28
Op. Cash Flow
$16.47B
Free Cash Flow
$12.36B
Gross Profit
$48.63B
Cash & Equivalents
$14.56B
Total Debt
$49.05B
Debt / Equity
0.93×
Net Margin
28.1%
Shares Outstanding
2.5B sh
Source: 10-K · filed 2026-02-24 · accession 0000310158-26-000063
$119.25 +0.20% today
52-week range · as of 2026-05-22 $75.4 – $125.14
Market cap
$294.03B
Volume
10.9M (1.1× avg)
3-mo avg 9.7M
Live data · 2026-06-13 15:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MRK - Filings & News (Page 2)

MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $123.49
Real-time Price: $119.25 info
Change: -$4.24 (-3%) info
Market Cap: $294.033B info
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $118.10
Real-time Price: $119.25 info
Change: +$1.15 (+0.98%) info
Market Cap: $294.033B info
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $118.06
Real-time Price: $119.25 info
Change: +$1.19 (+1%) info
Market Cap: $294.033B info
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $119.27
Real-time Price: $119.25 info
Change: -$0.018 (-0.02%) info
Market Cap: $294.033B info
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $116.68
Real-time Price: $119.25 info
Change: +$2.57 (+2%) info
Market Cap: $294.033B info
MRK
Mar 24, 2026, 9:03 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $116.68
Real-time Price: $119.25 info
Change: +$2.57 (+2%) info
Market Cap: $294.033B info
MRK
Mar 05, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $115.78
Real-time Price: $119.25 info
Change: +$3.47 (+3%) info
Market Cap: $294.033B info
MRK
Feb 28, 2026, 10:08 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $123.31
Real-time Price: $119.25 info
Change: -$4.06 (-3%) info
Market Cap: $294.033B info
MRK
Feb 28, 2026, 10:03 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $123.31
Real-time Price: $119.25 info
Change: -$4.06 (-3%) info
Market Cap: $294.033B info
MRK
Feb 27, 2026, 10:28 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $121.49
Real-time Price: $119.25 info
Change: -$2.23 (-2%) info
Market Cap: $294.033B info
MRK
Feb 27, 2026, 10:24 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $121.41
Real-time Price: $119.25 info
Change: -$2.16 (-2%) info
Market Cap: $294.033B info
MRK
Feb 24, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $124.00
Real-time Price: $119.25 info
Change: -$4.75 (-4%) info
Market Cap: $294.033B info
MRK
Feb 03, 2026, 6:38 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $112.00
Real-time Price: $119.25 info
Change: +$7.25 (+6%) info
Market Cap: $294.033B info